Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

Abstract Background Despite strong evidence of benefit, uptake of newer glucose-lowering medications that reduce cardiovascular risk has been low. We sought to examine global trends and predictors of use of SGLT2i and GLP-1 RA in patients with type 2 diabetes. Methods DISCOVER is a global, prospecti...

Full description

Bibliographic Details
Main Authors: Suzanne V. Arnold, Fengming Tang, Andrew Cooper, Hungta Chen, Marilia B. Gomes, Wolfgang Rathmann, Iichiro Shimomura, Jiten Vora, Hirotaka Watada, Kamlesh Khunti, Mikhail Kosiborod
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Endocrine Disorders
Subjects:
Diabetes
Cardiovascular disease
Quality of care
Online Access:https://doi.org/10.1186/s12902-022-01026-2

Internet

https://doi.org/10.1186/s12902-022-01026-2

Similar Items